Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 37,542 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

37,542 Papers indexed
371 Papers AI scored
37,542 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

37542 results
B
[Treatment of pediatric chronic myeloid leukemia].
PMID 41034077 Published: 2025-01-01 Ingested: 2026-08-02 12:03 AM [Rinsho ketsueki] The Japanese journal of clinical hematology
AI -
Base 71.34
Rank 71.34
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 34.2; sample size: 20.0; recency: 90.0; abstract quality: 65.0.

B
Caregivers' Perspectives on Changes in Family Life During B-ALL Therapy: A Qualitative Study From the Children's Oncology Group.
PMID 40974099 Published: 2025-09-19 Ingested: 2026-08-02 12:05 AM Pediatric blood & cancer
AI -
Base 71.34
Rank 71.34
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 54.2; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.
PMID 40448577 Published: 2025-05-31 Ingested: 2026-08-02 12:04 AM Journal of clinical oncology : official journal of the American Society of Clinical Oncology
AI -
Base 71.34
Rank 71.34
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 64.2; sample size: 60.0; recency: 90.0; abstract quality: 100.0.

B
Safety and Efficacy of Selective Internal Radiation Therapy for Portal Vein Tumour Thrombus in Advanced Hepatocellular Carcinoma: A Single-Centre Experience in Australia.
PMID 39913851 Published: 2025-02-06 Ingested: 2026-08-02 12:03 AM Journal of medical imaging and radiation oncology
AI -
Base 71.34
Rank 71.34
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 54.2; sample size: 80.0; recency: 90.0; abstract quality: 100.0.

B
Treatment Outcomes and Definition Inconsistencies in High-Risk Unilateral Retinoblastoma.
PMID 39332513 Published: 2024-09-25 Ingested: 2026-08-02 12:02 AM American journal of ophthalmology
AI -
Base 71.34
Rank 71.34
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 54.2; sample size: 80.0; recency: 90.0; abstract quality: 100.0.

B
Precision Medicine in Childhood Cancer: The Influence of Genetic Polymorphisms on Vincristine-Induced Peripheral Neuropathy.
PMID 39201483 Published: 2024-08-13 Ingested: 2026-08-02 12:02 AM International journal of molecular sciences
AI -
Base 71.34
Rank 71.34
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 64.2; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
AI -
Base 71.34
Rank 71.34
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 54.2; sample size: 90.0; recency: 80.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 91.7; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

B
Clinical Outcomes of Reduced-Dose Cabozantinib as Third- or Later-Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real-World Study.
PMID 41307601 Published: 2025-11-27 Ingested: 2026-08-02 12:05 AM Hepatology research : the official journal of the Japan Society of Hepatology
AI -
Base 71.32
Rank 71.32
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 71.3/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 69.1; sample size: 40.0; recency: 100.0; abstract quality: 100.0.

Previous
Page 492 of 3129
Next
Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic